What have we learned from brucellosis in the mouse model?

Authors: Grilló MJ,Blasco JM,Gorvel JP,Moriyón I,Moreno E,
Address: Programa de Investigación en Enfermedades Tropicales, Escuela de Medicina Veterinaria, Universidad Nacional, Heredia, Costa Rica. emoreno@medvet.una.ac.cr.
Journal: Vet Res.


Publication: 2012 Apr 13;43(1):29. doi: 10.1186/1297-9716-43-29.
Free Text: What have we learned from brucellosis in the mouse model?

abstract

ABSTRACT: brucellosis is a zoonosis caused by Brucella species. Brucellosis research in natural hosts is often precluded by practical, economical and ethical reasons and mice are widely used. However, mice are not natural Brucella hosts and the course of murine brucellosis depends on bacterial strain virulence, dose and inoculation route as well as breed, genetic background, age, sex and physiological statu of mice. Therefore, meaningful experiments require a definition of these variables. Brucella spleen replication profiles are highly reproducible and course in four phases: i), onset or spleen colonization (first 48 h); ii), acute phase, from the third day to the time when bacteria reach maximal numbers; iii), chronic steady phase, where bacterial numbers plateaus; and iv), chronic declining phase, during which brucellae are eliminated. This pattern displays clear physiopathological signs and is sensitive to small virulence variations, making possible to assess attenuation when fully virulent bacteria are used as controls. Similarly, immunity studies using mice with known defects are possible. Mutations affecting INF-γ, TLR9, Myd88, Tγδ and TNF-β favor Brucella replication; whereas IL-1β, IL-18, TLR4, TLR5, TLR2, NOD1, NOD2, GM-CSF, IL/17r, Rip2, TRIF, NK or Nramp1 deficiencies have no noticeable effects. Splenomegaly development is also useful: it correlates with IFN-γ and IL-12 levels and with Brucella strain virulence. The genetic background is also important: Brucella-resistant mice (C57BL) yield lower splenic bacterial replication and less splenomegaly than susceptible breeds. When inoculum is increased, a saturating dose above which bacterial numbers per organ do not augment, is reached. Unlike many gram-negative bacteria, lethal doses are large (≥ 108 bacteria/mouse) and normally higher than the saturating dose. Persistence is a useful virulence/attenuation index and is used in vaccine (Residual Virulence) quality control. Vaccine candidates are also often tested in mice by determining splenic Brucella numbers after challenging with appropriate virulent brucellae doses at precise post-vaccination times. Since most live or killed Brucella vaccines provide some protection in mice, controls immunized with reference vaccines (S19 or Rev1) are critical. Finally, mice have been successfully used to evaluate brucellosis therapies. It is concluded that, when used properly, the mouse is a valuable brucellosis model.



Related Articles
Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export.
PLoS One. 2008
Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export.
González D, Grilló MJ, De Miguel MJ, Ali T, Arce-Gorvel V, Delrue RM, Conde-Alvarez R, Muñoz P, López-Goñi I, Iriarte M, et al. PLoS One. 2008 Jul 23; 3(7):e2760. Epub 2008 Jul 23.
Role of TLRs in Brucella mediated murine DC activation in vitro and clearance of pulmonary infection in vivo.
Vaccine. 2012
Role of TLRs in Brucella mediated murine DC activation in vitro and clearance of pulmonary infection in vivo.
Surendran N, Hiltbold EM, Heid B, Akira S, Standiford TJ, Sriranganathan N, Boyle SM, Zimmerman KL, Makris MR, Witonsky SG. Vaccine. 2012 Feb 14; 30(8):1502-12. Epub 2012 Jan 9.
Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice.
Infect Immun. 2002
Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice.
Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Infect Immun. 2002 Dec; 70(12):7004-12.
Review Macrophages and Brucella.
Immunol Ser. 1994
Review Macrophages and Brucella.
Baldwin CL, Winter AJ. Immunol Ser. 1994; 60:363-80.
Review The innate immune response against Brucella in humans.
Vet Microbiol. 2002
Review The innate immune response against Brucella in humans.
Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP. Vet Microbiol. 2002 Dec 20; 90(1-4):383-94.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.